4/3
06:02 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its "outperform" rating re-affirmed by analysts at Citigroup Inc..
Medium
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its "outperform" rating re-affirmed by analysts at Citigroup Inc..
4/2
07:00 am
aura
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
Medium
Report
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
3/24
04:01 pm
aura
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Medium
Report
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
3/24
09:36 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
3/24
07:00 am
aura
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
Medium
Report
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress
3/3
07:07 am
aura
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress [Yahoo! Finance]
Medium
Report
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress [Yahoo! Finance]
3/3
07:00 am
aura
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
Medium
Report
Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress
2/25
07:00 am
aura
Aura Biosciences to Participate in Upcoming Investor Conferences
Low
Report
Aura Biosciences to Participate in Upcoming Investor Conferences
2/1
05:58 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.